Fezolinetant
Also known as: Veoza
A non-hormonal oral treatment for moderate to severe vasomotor symptoms (hot flushes and night sweats) associated with menopause. Fezolinetant is a neurokinin 3 (NK3) receptor antagonist, approved by NICE in 2024. It offers an alternative for women who cannot or prefer not to take HRT.
This page contains self-reported experiences from the Narrated community — not clinical data. Outcomes are subjective. Always consult your doctor or specialist before starting, stopping, or changing any approach.
Regulatory status does not mean an approach is safe or unsafe. Laws vary by country — check your local regulations.
Community Experiences
0 reports from women who tried Fezolinetant
No one has reported on this approach yet.
Be the first to share an experience.
Research Context
Research context compiled from published sources
How does Fezolinetant work?
Selectively blocks neurokinin 3 (NK3) receptors in the hypothalamic thermoregulatory centre (KNDy neurons). Oestrogen decline in menopause leads to overactivity of kisspeptin, neurokinin B, and dynorphin neurons, which dysregulates the thermoneutral zone and triggers hot flushes. By blocking NK3 receptors, fezolinetant restores thermoregulatory stability without affecting oestrogen levels.
Research Depth
Well Studied
Extensive human research over many years, including randomized controlled trials.
Long-Term Evidence
Limited
Only short-term data available. Long-term effects are not well understood.
Known Interactions
Reported Contraindicated Populations
Published Dose Ranges
Dose ranges from published research. Individual dosing should be determined with your healthcare provider based on your specific circumstances.
Factual research context from published sources — not a safety assessment or recommendation. Research classifications may change as new data emerges.
Related Approaches
Other approaches tracked on Narrated.
Data last updated: No data yet